The psychology of investing presents an interesting conundrum. When a stock soars, the natural tendency is to want to get in on the …
With near-term financing overhang removed and more confident in Iluvien’s sales growth, Cowen analyst Boris Peaker upgrades shares of Alimera Sciences Inc (NASDAQ:ALIM) from Market …
Merrimack Pharmaceuticals Inc Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares closed down over 6% Friday, after the cancer drug maker reported second-quarter results, with net Onivyde sales …
In a research report released Tuesday, Cowen analyst Boris Peaker reiterated a Market Perform rating on shares of Alimera Sciences Inc (NASDAQ:ALIM), with a …
Cantor analyst Caroline Corner initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) with a Buy rating and a $10 price target, which represents a potential upside of 72% …
